儿童造血细胞移植与免疫效应细胞治疗后PICU收治及早期重症管理国际专家共识
该共识由ESPNIC、PALISI网络HCT-癌症免疫治疗亚组和EBMT儿科疾病工作组制定,针对接受造血细胞移植与免疫效应细胞治疗(HCT-IEC)后10-35%出现危重症的患儿,形成27条关于PICU收治和早期重症管理的专家共识声明。20条获强烈同意,7条获弱同意,旨在指导重症、血液和肿瘤医生临床决策并优先未来研究。
要点
- HCT-IEC后10-35%患儿因疾病并发症或治疗毒性出现危重症。
- 共识含27条声明,20条强烈同意、7条弱同意。
- 声明指导PICU收治与早期重症管理,供重症、血液和肿瘤医生使用。
核心结论
- 该国际专家共识为HCT-IEC后儿科患者的PICU收治和早期重症管理提供指导,并可作为未来研究优先方向的基础。
研究设计与样本
- 由ESPNIC、PALISI网络HCT-癌症免疫治疗亚组和EBMT儿科疾病工作组制定专家共识声明。
- steering committee起草27条声明,由20名HCT和IEC领域专家投票。
主要发现
- 27条声明中20条获强烈同意,7条获弱同意。
- 接受HCT-IEC的患者中10-35%因疾病相关并发症或治疗相关毒性出现危重症。
关键数值与推荐
- 27条声明中20条获强烈同意,7条获弱同意。
- 接受HCT-IEC的患者中10-35%出现危重症。
临床怎么用
- 供重症医生、血液科医生和肿瘤科医生在HCT-IEC后患者PICU收治和重症管理过程中参考使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in paediatric haematopoietic cell transplantation strategies using immune-effector cells (HCT-IEC) and in intensive care management have improved survival expectations for patients with malignant and non-malignant diseases. However, critical illness still complicates the clinical course for 10-35% of patients undergoing HCT-IEC because of disease-related complications or treatment-related toxicities. Given the improvement in survival for these patients in paediatric intensive care units (PICU), the European Society of Paediatric and Neonatal Intensive Care (ESPNIC), the HCT-Cancer Immunotherapy Subgroup of the Paediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, and the Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) derived expert consensus statements to guide PICU admission and early critical care management of patients following HCT-IEC. 27 statements were drafted by the steering committee and subsequently voted on by 20 expert panel members with expertise in HCT and IEC. 20 statements received strong agreement and seven received weak agreement. This consensus statement serves as a guide for intensivists, haematologists, and oncologists during the challenging process of PICU admission and critical care management of patients who have undergone HCT-IEC and can serve as a basis for prioritising future research in the field.
引用
- Di Nardo M, Ghafoor S, Szmit Z, et al. International expert consensus statement on PICU admission and early critical care management for paediatric patients following haematopoietic cell transplant and immune effector cell therapy. Lancet Child Adolesc Health. 2025. PMID: 40379432. doi:10.1016/S2352-4642(25)00091-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。